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ABSTRACT
NEURONAL TOXICITY OF HUMORAL FACTORS FROM PATIENTS WITH 
DIABETIC NEUROPATHY AND MECHANISM OF NEURONAL DEATH ON 
CULTURED ADRENERGIC NEURONS
STUDIES OF AUTOIMMUNE PATHOGENESIS IN DIABETIC NEUROPATHY
Dong Liu
Eastern Virginia Medical School/Old Dominion University, 1996 
Director: Dr. Gary L. Pittenger
Diabetic neuropathy is an extremely common medical problem because of the high 
frequency of diabetes and its complications. Diabetic neuropathy consists of not one, but 
many patterns of nerve injury, each potentially with its own discrete pathogenic 
mechanisms. Evidence is accumulating that indicates autoimmunity plays a role in diabetic 
peripheral neuropathy. However, the significance of immunopathogenesis of diabetic 
neuropathy is as yet unclear.
Using the N1E-L15 mouse neuroblastoma cell line (NB) as a model of the 
adrenergic autonomic neuron, we found that sera of IDDM patients with neuropathy inhibit 
growth and differentiation of adrenergic neurons in culture (Pittenger et al, 1993; 1995). 
Some sera were cytotoxic and caused neuronal death. Further characterization of the 
inhibiting, or toxic, factor in EDDM patient serum indicated that it had the properties of an 
immunoglobulin. The toxic factor was present in the immunoglobulin fraction, and was 
pre-absorbed by neuroblastoma cells and protein A beads. Immunocytochemistry revealed 
a specific cell-surface binding pattern of immunoglobulin IgG which suggested the 
presence of an antibody recognizing antigens on the neuroblastoma cell surface. Moreover, 
the inhibiting effect of IDDM serum could be reversed by heat inactivation, indicating the 
possible involvement of complement.
Further investigation revealed that the neuronal death induced by EDDM serum 
occurred through the programmed cell death mechanism, apoptosis, which was
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characterized by cell shrinkage, cytoplasm condensation and DNA fragmentation. A 
sustained increase of cytosolic calcium concentration was detected by Fura-2, a 
fluorescence indicator, at an early stage after exposure to IDDM serum. Apoptosis-related 
protein expression was also examined in our model. Fas, a cell-surface receptor, seemed 
to be expressed at the N1E-115 cell surface and recognized by IDDM serum. Whether it 
was the antigen involved in apoptotic cell death or whether other antigens were also 
involved remains to be further determined.
In conclusion, autoimmune-related humoral factors in the semm from EDDM 
patients with neuropathy had an ability to inhibit neuronal cell growth and differentiation, in 
some cases inducing cell death by apoptosis in cultured adrenergic neurons. However, 
because N1E-115 cell was a murine tumor cell line, the significance of the findings to 
diabetic neuropathy and clinical correlation needs to be further evaluated. These studies 
indicated that immunopathogenesis may play an important role in the development of 
diabetic neuropathy in IDDM patients.
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Chapter 1. Background and Significance I
CHAPTER I. BACKGROUND AND SIGNIFICAMCE
1.1. Diabetic Neuropathy and its pathogenesis
Diabetic neuropathy develops as a significant complication in patients with all forms 
of diabetes mellitus. Estimates of the prevalence of neuropathy in the population of patients 
with diabetes range from 10-50% (Boulton et al., 1985; Newrick et al., 1986; Harati, 
1992), dependent on the criteria used to define neuropathy. Diabetic neuropathy is an 
insidious degenerative disease of peripheral nerves. The most common form, distal 
symmetrical sensorimotor neuropathy, afflicts sensory, motor and autonomic nerves. It has 
a predilection for neurons with the longest axons and shows fiber loss in the more remote 
nerve trunks. The loss of sensation predisposes the patients to lesions, especially o f the 
foot, potentially resulting in gangrene and amputation. In other cases, focal and multifocal 
neuropathy are asymmetrical, and might affect cranial, trunk or limb innervation. Many of 
the diabetic neuropathic syndromes are characterized by painful symptoms with a sensation 
of burning and associated with troublesome hyperesthesia (Vinik et al., 1988; 1992; 1994;; 
Brewster et al., 1994; Boulton et al., 1986).
Autonomic neuropathy is a serious component o f  diabetic neuropathy, heralding 
mortality rates o f 25-50% within 2-3 years of diagnosis o f autonomic neuropathy (Vinik et 
al., 1988, 1992; Ewing et al., 1976; 1982; O'Brien et al., 1986). Diabetic autonomic 
neuropathy may manifest as dysfunction of several different organ systems: cardiovascular, 
gastrointestinal, genitourinary, sudomotor, and ocular. The symptoms are important in 
individual patients, but difficult to evaluate and quantitate, because they are often 
nonspecific (Julius, 1991). Symptoms can occur as early as the first year after diagnosis, 
presenting as a combination of the following: orthostatic hypotension, diminished 
sweating, diarrhea or constipation, hypoglycemic unawareness, urinary dysfunction, 
impotence, delayed gastric emptying, alternating bouts of diarrhea and constipation,
•»
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Chapter 1. Background and Significance 2
bladder atony and/or exercise intolerance (Pfeifer et al., 1984; O'Brien et al., 1986). 
Cardiac conduction abnormalities may lead to cardiorespiratory arrest and resting 
tachycardia. Autonomic neuropathy is associated with an increased mortality from renal 
failure and an increased frequency of retinopathy and peripheral neuropathy (O'Brien et al.,
1991).
The most important pathological changes in diabetic neuropathy are loss of 
myelinated and unmyelinated axons, demyelination and axonal degeneration (Dyck et al, 
1986). Distal nerves are more affected than proximal nerves, as determined by postmortem 
nerve fiber density (Chopra et al., 1971). Subtle changes at the nodes of Ranvier along 
diabetic human nerve, including paranodal swelling and alterations of Schwann cell 
attachments, termed axo-glial dysjunction are described (Sima et al., 1988).
In contrast to other peripheral neuropathy, autonomic nerve damage is confined to 
small, predominantly unmyelinated nerve fibers. Pathologic changes in the autonomic 
nervous system studied from postmortem samples of diabetic patients with severe 
autonomic neuropathy reflect severe loss o f myelinated fibers and degeneration. Adrenal 
medullary fibrosis was found in a retrospective pathology study in EDDM patients with 
long duration (Brown et al., 1989). Infiltration of lymphocytes and macrophages is seen in 
autonomic ganglia and in or around autonomic nerve bundles of unmyelinated nerve fibers, 
suggesting that a different pathogenesis may be involved in the development of autonomic 
neuropathy in diabetes (Duchen et al., 1980).
Most discouraging, the cause of diabetic neuropathy is uncertain and an effective 
treatment has not been identified. Several independent modifying factors and multiple 
pathogenetic mechanisms, some of which have been researched extensively, may interact to 
produce neuropathy (Ward, 1989). The current hypotheses include:
1. Chronic hyperglycemia and/or insulin deficiency are the primary factors in the 
causation of diabetic neuropathy (Winegrad et al., 1977). There is evidence that the 
incidence and severity of complications secondary to diabetes correlate with the degree of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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metabolic control (DCCT, 1993). Hyperglycemia results in intracellular accumulation of 
toxic metabolic products such as sorbitol, fructose, galactitol and advanced glycosylation 
end products. Increased polyol-pathway activity and decreased sodium dependent myo­
inositol uptake content, reduced energy use and defective function of (Na, K)-ATPase have 
been described (Greene et al., 1988; 1989; Stevens et al., 1993; 1994), ail of which may be 
responsible for osmotic stress and diminished nerve conduction velocity. Impaired Na-K- 
ATPase activity also appears to be responsible for intracellular Na+ accumulation and 
resultant localized axonal paranodal swelling that characterizes diabetic neuropathy in both 
humans and laboratory animals (Dyck et al., 1988).
2. Depletion or alteration of neurotrophic growth factors may cause neuronal 
dysfunction in diabetes. A variety of neurotrophic factors are necessary for normal 
growth, development, maintenance and regeneration of the peripheral nervous system. 
Physiological concentrations of insulin, IGF-I or IGF-II reversibly enhance neurite 
outgrowth and increase the contents of neurofilament, alpha-tubulin, and beta-tubulin 
mRNAs in cultured human neuroblastoma SH-SY5Y cells (Wang et al, 1992; Recio et al, 
1984). Neurotrophic factor accessibility and action may be diminished in diabetes due to 
defective transport and post-receptor signal transduction or due to reduced levels of 
circulating growth factors (Faradji et al., 1990; Schmidt et al., 1993).
3. Microvascular insufficiency may contribute to diabetic neuropathy. Endothelial 
cell swelling and proliferation, as well as platelet aggregation resulting in vessel occlusion 
have been noted in the pathogenesis of diabetic neuropathy. The diabetic nerve is also 
more susceptible to ischemia and death (Tuck et al., 1984; Dyck et al., 1986). Endoneurial 
capillary density is significantly reduced in severely neuropathic diabetic patients when 
compared with control subjects (Malik et al., 1989). It is possible that altered peripheral 
blood flow leads to increased spontaneous activity in nociceptive afferent fibers that are 
present in the axonal sprouts that characterize small fiber neuropathy (Boulton et al., 1986).
4. Autoimmunity may play an important role in the development of diabetic
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neuropathy. The awareness of the immunological process as one of the possible 
pathogenetic mechanisms in diabetic neuropathy has increased, especially in EDDM 
patients. Although it has been questioned, immunological processes are strongly 
associated with diabetic autonomic neuropathy, indicated by clinical, morphological, 
serological and cellular observations (Sundkvist et al., 1994). A  role for autoimmunity in 
the pathogenesis o f diabetic neuropathy is as described below.
1.2. The role of autoimmunity in diabetic neuropathy
IDDM is a chronic autoimmune disease with a long prodromal phase, during which 
antibodies that react with islet cells are often present (Bottazzo et al., 1986). Autoimmunity 
is a known factor in the pathogenesis of islet cell destruction (Herold et al., 1992; Boitard,
1992), but little is known of its role in the pathogenesis o f the neuropathy complications of 
diabetes.
Because diabetic neuropathy in IDDM patients is a common complication of the 
autoimmune disease, they may share some common immunological defects or genetic 
background. There are many similarities between islet cells and neurons. Some neuronal 
cell-surface markers, such as tyrosine hydroxylase for neurons, are also present on 
pancreatic islets, suggesting a possible common origin of pancreatic islet cells and neurons 
(Pearse, 1982). Neurons release neurotransmitters in much the same manner as pancreatic 
islets release hormone in response to stimuli. There are antigens shared between islet cells 
and neurons such as gangliosides (Nayak et al, 1985) and glutamic acid decarboxylase 
(GAD) (Clare-Salzler et al., 1992; Kaufman et al., 1992; Esclapez et al., 1994). Because 
of these similarities between islet cells and neurons, it is thought that the immunological 
process directed against islet cells could also attack neurons. Thus, a role for the 
immunopathological process in pathogenesis of diabetic neuropathy should be considered.
The humoral immunity in diabetic neuropathy
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The capacity to produce autoantibodies is an inherent property of the normal 
immune system. The vast immunoglobulin repertoire gives B cells the potential to produce 
autoantibodies against a list of autoantigens. Nevertheless, autoantibodies, including 
natural autoantibodies, never appear against autoantigens in normal conditions, probably 
because of deletion or anergy of particular autoreactive T-cell and B-cell clones early in 
ontogeny. However, the traditional theory about self-nonself being distinguished and 
tolerance established in the neonatal period has been questioned recently (Pennisi, 1996). 
It has been suggested that the dendritic cells and B cells of the immune system may regulate 
immune activation and immune tolerance. If B cells fail to inactivate the dendritic cells 
presenting autoantigens, autoimmunity may result ( Ridge et al, 1996).
Evidence indicates that in diabetic patients with autonomic neuropathy, there are 
complement-fixing autoantibodies against autonomic nerve tissue components in 
sympathetic ganglia, adrenal medulla and vagus nerve (Brown et al., 1989; Rabinowe et 
al., 1990; Zanone et al., 1993.). Anti-ganglioside G T lb  IgG, associated with both 
sympathetic ganglia and adrenal medulla antibodies, has been reported in IDDM patients 
with neuropathy and is inversely related to the change in orthostatic blood pressure 
(Rabinowe et al., 1991). In one study, sera of 120 IDDM patients were examined for the 
presence of complement-fixing anti-sciatic nerve antibodies and 22% had fluorescent scores 
exceeding normal control subjects (MacLaren et al., 1989). If these antibodies attack 
neuronal tissue, they should be detectable in nerve tissues as they are attacked. 
Immunoglobulin deposition in the perineurial regions and axons has been noted in nerve 
biopsies from diabetic patients with neuropathy (Graham et al, 1985; Schenone et al, 1988; 
Milicevic et al, 1995).
Clinical evidence suggests that immune therapy is effective in diabetic neuropathy, 
further supporting the notion that immune processes may be involved in the pathogenesis 
of autoimmune-mediated neuropathy. Plasmapheresis alleviates neuropathy associated 
with anti-myelin IgM (Haas et al., 1988). Plasma exchange in neuropathy patients with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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IgA and IgG gammopathies, effectively attenuates neuropathy based on disability score, 
muscle weakness and compound motor nerve action potentials (Dyck et al., 1991). High 
dose intravenous immunoglobulin (IVIg) treatment is effective in patients with a variety of 
neuropathies associated with autoimmunity, including diabetic neuropathy (Nobile et al., 
1993; Karlson et al., 1994; Krendel et al, 1995). However, the mechanism by which IVIg 
acts is uncertain.
In many studies (Brown et al., 1989; Rabinowe et al., 1990; Zanone et al., 1993), 
autoantibodies against autonomic nerve tissue components tend to appear more frequently 
in the neuropathic patients than in the diabetic control subjects with disease of similar 
duration, suggesting that neuronal tissue autoantibodies may have a role in the development 
of symptomatic diabetic neuropathy. However, it is not understood whether these 
autoantibodies are primary causes (directly causing neuronal tissue damage and playing a 
role in pathogenesis of neuropathy), or secondary effects of the neuropathy due to 
exposure of autoantigens after neuronal tissue damage. It is also possible that 
autoantibodies raised secondarily to neuronal damage may accelerate the neuronal loss, thus 
still playing an important role in the development of neuropathy. Populations studies have 
noted the presence o f complement-fixing antibody against adrenal medullary in 30% of 
IDDM patients, which decrease in patients with diabetes for greater than 16 years (Brown 
et al., 1989), suggesting that antibody may play an early causative role in the development 
of neuropathy. Autoantibody against sympathetic ganglia is associated with a diminished 
catecholamine response to changes in posture and orthostasis in IDDM patients (Brown et 
al, 1989), supporting the idea that the adrenergic nervous system is a target for autoimmune 
destruction.
Autoantibodies detected in sera of patients with neurological disease have been 
reported in chronic inflammatory demyelinating polyneuropathy (Weng et al., 1992), 
myasthenia gravis (Rowland et al., 1991), Stiff-man syndrome (Pugliese et al., 1993; 
Solimena et al., 1988: 1990), Guillain-Barre syndrome (Quarles et al., 1990), lower motor
4
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neuron disease (Freddo et al., 1986), multiple sclerosis (McFarland et al. 1989). and acute 
post-infectious disseminated encephalomyelitis (Segal, 1983). Circulating antibodies may 
also play a pathogenetic role in neuropathies associated with amyloidosis, myeloma, 
macroglobulinemia, lymphoma, and certain leukemias (Dyck et al., 1991). It appears that 
the location of the presumptive target antigen critically influences the pathogenetic potential 
of autoantibodies. Autoantibodies directed against cell-surface targets are often 
pathogenetic, such as in myasthenia gravis (characterized by autoantibodies against the 
acetylcholine receptor in membranes of skeletal muscle fibers) (Schonbeck et al., 1990). 
Those directed against extracellular matrix components may or may not cause damage. 
Antigens may be both cytoplasmic or exposed on the cell surface, such as 64-kDa islet cell 
antigen or GAD (glutamic acid decarboxylase), an enzyme involved in the synthetic 
pathway of the inhibitory neurotransmitter, gamma-aminobutyric acid (Kaufman et al.,
1992).
The Cellular immunity in diabetic neuropathy
The cellular immune system is the engine of all immunity, including antibody 
production. A role for cell-mediated immunity to nervous system antigens in the 
pathogenesis of diabetic neuropathy has also been suggested (Segal et al., 1983; Gilbey et 
al., 1988). In tissue samples from diabetic patients with severe autonomic neuropathy, 
inflammatory infiltrates composed o f lymphocytes, macrophages and occasional plasma 
cells are seen in autonomic ganglia and in or around autonomic nerve bundles of 
unmyelinated nerve fibers (Duchen et al., 1980). In a group of similar patients, an 
increased level of circulating activated T lymphocytes was observed, suggesting a role of 
the cellular immune system in the pathogenesis of neuropathy (Gilbey et al., 1988). Levels 
of activated T lymphocytes are increased in newly diagnosed Type 1 diabetic patients, but 
tend to return to normal within 2-3 years. Their persistence or, possibly, reappearance in 
diabetic neuropathy may represent continuing immune activation against neuronal targets
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(Zanone et ai., 1993). It is unknown whether the generation of antibody preceded this 
immune infiltration.
There is evidence using the lymphocyte transformation technique, that lymphocytes 
from some patients with diabetic neuropathy undergo significant stimulation when cultured 
in vitro in the presence of both CNS and PNS basic protein antigen (encephalitogenic 
protein and P2) (Segal et al., 1983). Cell-mediated immunity to neural antigens has also 
been reported in myeloradiculitis, chronic relapsing polyneuritis (Abramsky et al., 1975) 
and transverse myelopathy (Abramsky et al., 1977).
Autoantigen Identification
Identifying and characterizing the relevant autoantigens is still a challenge in 
destructive organ-specific autoimmunity, but it might lead to advances in diagnosis, 
treatment and even prevention of autoimmune diseases.
Data from studies of animal diabetes and autoantibodies in IDDM suggest that 
many epitopes or antigen structures become autoantigens during disease pathogenesis. 
Previous studies on antibodies to autonomic nervous structures indicated a higher 
prevalence of these antibodies in recent-onset Type 1 diabetic patients, who were ICA (islet 
cell cytoplasmic antigen) positive, than in those with long-term diabetes. This suggests that 
antibodies to nerve tissue and ICA may have target antigens in common (Brown et al., 
1989). However, in other studies no significant correlation between anti-nerve tissue 
autoantibodies and ICA or other conventional tissue autoantibodies was found. Therefore, 
antibodies to nerve tissue may occur independently and the target antigens are tissue 
specific (Zanone et al., 1993).
a. Gangliosides
Studies suggest that the autoantigens of pancreatic tissues have the properties of a 
glycolipid containing sialic acid (Nayak et al., 1985; Powers et al., 1984; Dotta et al., 
1989). This may account for the failure to detect islet-cell surface antibodies with
4
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processes utilizing organic solutions (Vives et al., 1992). Monoclonal anti-ganglioside 
antibodies produced by immunization with fetal rat brain react specifically with all cell 
surfaces of pancreatic islets of human, rat, mouse (Ariga et al., 1987). It is generally 
thought that in organ-specific autoimmune diseases, the autoantibodies are specific for each 
organ and do not cross-react (Bottazzo et al., 1986). However, some islet cell antigens 
(e.g., gangliosides) are present in significant amounts in other organs besides pancreatic 
islets, such as neurons, renal glomerular cells, retinal microvascular pericytes and adrenal 
medulla. Thus, it is possible that the common antigens may be involved in multiple organ 
damage and may cause diabetic complication, such as neuropathy, retinopathy and 
nephropathy (Nayak, et al., 1985; Eisenbarth et al., 1988).
Anti-ganglioside antibodies have been found in Guillain-Barre syndrome (Quarles 
et al., 1990; Ilyas, 1988), lower motor neuron disease (Freddo et al., 1986;), chronic 
inflammatory polyneuropathy (Baba, 1989), multiple sclerosis (Endo et al., 1984), and 
amyotrophic lateral sclerosis (Pestronk, 1988b), neuromuscular disease (Adama et al., 
1991), as well as neuropathy in type I diabetes (Rabinowe et al., 1991). Indeed, 
ganglioside GM1 treatment with formation of anti-ganglioside antibodies is associated with 
an increased incidence o f Guillain-Barre syndrome (Landi et al., 1993), suggesting a 
causative relationship for GM1 autoantibodies.
In neuroblastoma cells, gangliosides are abundant on cell surface membranes (Wu,
1991). The composition of gangliosides in different cell types or cell lines varies. IgM 
antibody that recognizes gangliosides GM1, G D lb and asialo-GMl is reported in motor 
neuron diseases such as lower motor neuron disease, multifocal motor neuropathy and 
acute axonal neuropathies (Latov et al., 1988; Geisler et al., 1991). Anti-ganglioside G Tlb 
IgG, associated with both sympathetic ganglia and adrenal medulla antibodies, is reported 
in IDDM patients with autonomic neuropathy (Rabinowe et al., 1991). Thus, ganglioside 
should be considered as an important candidate antigen in autoimmune-mediated diabetic 
neuropathy.
'd
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b. Myelin Basic Protein
Anti-myelin basic protein antibodies are reported in Guillain-Barre syndrome, 
multiple sclerosis and experimental allergic neuritis (EAN) induced in Lewis rats. 
Administration of myelin basic protein suppresses experimental autoimmune 
encephalomyelitis by neutralizing antibody (Khoury et al., 1990). Considerable evidence 
favors a role of anti-myelin antibody in mediating demyelinating polyneuropathy (Hays et 
al., 1987; Hafler et al., 1986; Steck et al., 1983). It remains to be determined whether anti­
myelin antibody plays a role in diabetic neuropathy.
c. Glutamic acid decarboxylase (GAO)
GAD is an enzyme involved in the synthesis of the neurotransmitter gamma amino- 
butyric acid (GABA). Antibody against GAD is present in sera o f  patients with type 1 
diabetes and GAD is considered to be an autoantigen in pancreatic islets (Clare-Salzler et 
al., 1992). GAD exists in two isoforms, 65kDa and 67kDa, that differ in their 
intraneuronal distributions (Kaufman et al, 1992). GAD67 is widely present in cell bodies, 
whereas GAD65 is prominent in many axon terminals (Esclapez, 1994). GAD67 and 
GAD65 are different gene products, with GAD67 the predominant form in neurons 
(Kaufman et al, 1992). Higher titers of anti-GAD antibodies have been reported in a small 
number of diabetic patients with autonomic neuropathy (Kaufman, 1992). O f interest, anti- 
GAD antibodies appear to cause the neurological disorder in Stiff-Man Syndrome, which is 
often accompanied by diabetes (Karlson et al., 1994). Because GAD antibodies may be 
involved in different diseases, the epitope on GAD recognized by antibodies may be critical 
to the physiological and disease-specific effects (Daw et al., 1996). Thus, anti-GAD 
antibody may play a role in diabetic neuropathy. However, several recent studies argue 
this may not be the case. Anti-GAD65 antibodies are present in a high proportion of 
patients with diabetic neuropathy, but are not exclusively associated with it. High 
prevalence of autoantibodies to GAD in long-standing IDDM is not a marker of 
symptomatic autonomic neuropathy (Zanone et al., 1994; Vinik et al., 1995). There is no
•d
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correlation between the presence of anti-GAD65 antibodies and the presence of 
autoantibodies to sympathetic ganglia, vagus nerve, or adrenal medulla structures identified 
by immunofluorescence. Nor are GAD-antibodies associated with disturbed autonomic 
nerve function (Sundkvist et al., 1994). Moreover, GAD is a cytoplasmic enzyme and 
access of the autoantibody to the protein is problematic. Thus, the role of anti-GAD 
antibodies in diabetic neuropathy remains elusive.
d. Nerve growth factor (NGF) and NGF receptor
Shared sequence homology between portions of the nerve growth factor (NGF) and 
pro-insulin molecules suggests an autoimmune mechanism acting through effects of anti­
insulin antibodies modifying NGF activity (Schmidt, 1993). Anti-insulin antibodies are 
common in IDDM patients and cross-reaction with NGF could lead to the immunologically- 
mediated destruction of nerve tissues that are depend on NGF. NGF stimulates and 
maintains growth and differentiation of sensory and sympathetic nerves and dorsal root 
ganglion cells during early development. NGF is also necessary for neuronal survival, 
morphology and function in maturity. NGF receptor TrkA knockout mice show deficient 
C-fiber function and lack sympathetic nerve development. An immune attack on NGF 
might result in damage to autonomic nerves, leading to neuropathy. Autoantibodies to 
NGF have been reported in the sera of patients with autoimmune diseases and diabetes 
(Dicou et al., 1993; Faradji et al., 1990). However, a recent investigation found no 
significant difference in anti-NGF antibody level among groups of diabetic patients with 
neuropathy, diabetic control patients and normal control subjects (Zanone et al., 1994). 
Any relationship between NGF and autoimmunity remains to be determined.
e. Other membrane lipids/protein components
Membrane lipids, such as phospholipids have been thought to be important in 
diabetic neuropathy (Greene et al., 1989; McNeil et al., 1991; Vinik et al., 1995). 
Membrane proteins, such as the voltage-dependent L-type calcium channel, have been 
suggested as autoimmune targets in the neurodegenerative diseases Lambert-Eaton
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myasthenic syndrome and amyotrophic lateral sclerosis (Leys, 1991; Smith, 1993). The 
frequency of anti-phospholipid antibody is significantly higher in diabetic neuropathy 
patients than in the general population or patients without neuropathy according to a recent 
study (Vinik et al., 1995). Anti-cardiolipin antibodies occur in autoimmune disease and a 
phospholipid-beta 2-glycoprotein I complex has been suggested to be the antigen (Hunt et 
al., 1992). A  significance of anti-phospholipid and anti-cardiolipin antibodies in the 
pathogenesis o f diabetic neuropathy has not been established.
1.3. Cellular mechanism of neuronal death
Recent studies indicate dysfunctional control of programmed cell death (apoptosis) 
is involved in the development of autoimmune diseases and neurodegenerative diseases 
(Thompson., 1995; Carson et al., 1993). One mechanism underlying autoimmunity is the 
defective ability of the immune system to delete self-reactive T and B lymphocytes by 
apoptosis, which could predispose to autoimmune disease. Some studies have 
demonstrated that apoptosis may also play a role in the pathogenesis of IDDM. It has been 
reported that IgM in sera from IDDM patients causes an increase in voltage-dependent L- 
type calcium channel activity of insulin-producing cells. The subsequent increase in the 
concentration of free cytoplasmic Ca2+ was associated with DNA fragmentation and 
apoptotic cell death (Berggren et al., 1993). More recently, genetic analysis of non-obese 
diabetic (NOD) mice showed that the apoptosis related gene bcI-2 mapped close to the 
gene region which is associated with periinsulitis. The bcl-2 NOD (non-obese diabetic) 
mouse haplotype is linked to an elevated serum IgG. Activated T lymphocytes from NOD 
mice also showed a marked resistance to induction o f apoptosis (Garchon et al., 1994). 
However, little is known about the relevance of apoptosis and the regulation of apoptosis 
to neuropathic complications in IDDM patients.
Apoptosis occurs through the activation of a cell-intrinsic program. The basic 
machinery to carry out apoptosis appears to be present in essentially all mammalian cells,
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at all times (Steller, 1995). Neurons also have a programmed cell death pathway. 
Approximately half of the neurons produced during embryogenesis normally die before 
adulthood. Apoptotic morphological changes and DNA fragmentation have been 
described in 3-day-old cultured cortical neurons exposed to glutamate (Kure et al., 1991). 
Target-derived neurotrophic factors are known to be major determinants of programmed 
neuronal cell death (Garcia et al, 1992). Sympathetic neurons undergo RNA-and protein 
synthesis-dependent programmed cell death when deprived of nerve growth factor 
(Deckwerth et al, 1993). In diabetic neuropathy, the most important pathological change 
is loss of myelinated and unmyelinated axons (Chopra et al, 1971; Brewster et al, 1994). 
This is similar to a wide variety of neurological diseases, such as Alzheimer’s disease, 
Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and 
various forms of cerebellar degeneration, which are characterized by the gradual loss of 
specific sets of neurons but without an obvious inflammatory reaction. In these diseases, 
apoptosis has been suggested to be the mechanism of neuronal cell death (Thompson, 
1995).
Apoptosis is characterized by condensation of cytoplasm, compacting of 
chromatin, formation of a convoluted plasma membrane and extensive fragmentation of 
chromosomal DNA into oligomers. The DNA ladder that forms during apoptosis results 
from the activation of an endogenous endonuclease. An increase of cytosolic calcium at an 
early phase of apoptosis may contribute to the activation of the endonuclease (Joseph et al,
1993). Meanwhile, there is no tissue inflammation. The suicide program is regulated by 
many extrinsic and intrinsic signals, and the threshold of apoptotic cell death is also 
dynamically regulated by multiple inducers and inhibitors of gene products (Steller, 1995). 
Removal of trophic factors, excessive exposure to excitatory amino acid neurotransmitters, 
oxidative stress, calcium toxicity and mitochondrial defects have all been postulated to 
contribute to the pathogenesis of apoptotic neuronal death.
Several apoptosis-related oncogene products are expressed and regulated in
•i
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neurons. Bcl-2, a cell death suppressor, is found in the mitochondrial membrane, the 
nucleus and the endoplasmic reticulum. A  high level of expression o f bcl-2 in sympathetic 
neurons prevents cell death induced by deprivation of nerve growth factor (Garcia et al,
1992).
Another important regulator of neuronal apoptosis is the low-affinity NGF receptor, 
p75, which appears to be important for neuronal cell death and survival (Rabizadeh et al.,
1993). p75 has been shown to increase the affinity of TrkA for NGF and to enhance the 
specificity of the Trk family of receptors for neurotrophins (Barbara et al., 1991). It is 
now apparent that p75 is yet another cellular death signaling protein (Finkel, 1996). p75 
has some sequence similarity to the tumor necrosis factor receptors (TNFR-I and TNFR- 
II), the human cell surface antigen Fas (APO-1), and the B cell antigen CD40, all of which 
mediate cell death through an intracellular "death domain" (Bazzoni, 1996). Because of 
structural and functional homology between the NGFR/TNFR system, the hypothesis that 
p75 serves as a constitutive cell death-promoting molecule that is inhibited by NGF binding 
was put forward (Finkel, 1996). Evidence suggested that because p75 enhanced the 
survival o f neurons from developing embryos, it might act as a death gene for older 
neurons. The type of cell death induced by p75 was apoptosis and neural cell survival was 
enhanced by binding of NGF to p75 (Rabizadeh et al., 1993). Recent studies have further 
supported the concept of p75 as a constitutive regulator of apoptosis and suggested that 
inhibiting p75 expression with antisense oligonucleotides can rescue neurons from death 
(Finkel, 1996).
Fas/APO-1 (APO-1, CD95), another member of the NGFR/TNFR family, is a 
type I cell-surface receptor with a molecular weight o f 35-40kDa. Binding of the receptor 
by ligand or antibody initiates cell death (Bazzoni, 1996). Fas-mediated apoptosis 
triggered by ligation of Fas molecule seems to be target dependent. For example, 
macrophages express Fas and undergo apoptosis when cultured with anti-Fas. In contrast, 
although endothelial cells can express the Fas molecule, Fas ligation is insufficient to
*
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induce apoptosis suggesting differential regulation of Fas function among cells 
(Richardson et al., 1994). The susceptibility of Fas-bearing cells to Fas/APO-1 antibody- 
mediated cell killing is also modulated by cytokines. Fas dependent cytotoxicity were 
augmented by pre-exposure to interferon gamma and TNF alpha in maligment glioma cells 
(Weller eta l, 1994).
Fas/APO-1 antigen was originally described in fibroblasts, some malignant 
tumor cell lines (Yonehara, 1989) and some cells o f lymphocyte lineage (Nagata, 1995). 
Subsequently, a variety of normal cells have been found to express this cell surface 
glycoprotein. In mice, the mRNA coding for Fas antigen is present in the thymus, heart, 
liver and ovaries (Watanabe-Fukunaga et al., 1992). In human tissue, Fas/APO-1 is 
expressed by epithelial cells, satellite cells o f the autonomic ganglia and some 
mesenchymal cells, such as fibroblasts and endothelial cells. Histiocytes and subsets of 
T- and B-Iymphocytes, as well as a number of malignant cells, also express the Fas/APO- 
1 antigen (Owen-Schaub et al., 1993). However, Fas expression has not been reported in 
neurons, although Fas antigen was found in brains of patients with Alzheimer-type 
dementia, mainly expressed by a subset of reactive astrocytes. These astrocytes may 
undergo the Fas-mediated apoptotic process (Nishimura et al., 1995).
The role o f Fas and Fas ligand in regulation of cytotoxic T  lymphocytes, 
especially in the pathogenesis of autoimmune diseases, has been noted (Hanabuchi et al.,
1994). For example, point mutation in the Fas cytoplasmic domain and Fas ligand in 
homozygous mice caused conditions termed Ipr (lymphoproliferation) or gld (generalized 
lymphoproliferative disease), which are similar to systemic lupus erythematosus, a human 
autoimmune disease with neurological complications (Nagata, 1995).
Many cell cycle-regulating genes, including several cyclins, c-fos, c-myc, c-jun, 
cdc-2, RB and p53 have been suggested as mediators of cell survival, division or 
apoptotic death (Pandey et al., 1995). p53, the protein product of a tumor suppresser 
gene, and inhibitor of cell mitosis, acts as a direct effector causing apoptosis.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 1. Background and Significance 16
Overproduction of normal p53 protein in a myeloid leukemia cell line induces rapid 
apoptotic cell death (Yonish-Rouach et al, 1991). What their role in neuronal cell death is 
remains to be explored.
1.5. Rationale
Diabetic neuropathy is a life-threatening complication in a significant proportion of 
patients with all forms of diabetes mellitus, whose etiology is unclear. Studies indicate the 
appearance of autoantibodies before clinical presentation, thus, progressive target cell 
destruction may develop over several years (Boitard, 1992). On these bases, it may be 
possible to identify individuals at high risk for development of EDDM and its neuropathic 
complications using specific genetic and immunological assays. This raises the possibility 
that effective immunotherapies could be developed to prevent the target cell destruction, 
while the individual still has substantial target cell reserves. The presence of autoantibodies 
to antigens contained in islet cells has become a reliable means of predicting future 
development of IDDM, although islet cell antibodies are heterogeneous and some antibodies 
may be more predictive than others (Eisenbarth et al., 1988). As mentioned before, 
autoantibodies against neuronal tissue may not be correlated with ICA (islet cell cytoplasmic 
antigen) antibodies. A method to predict diabetic neuropathy by measurement of antibodies 
to specific neuronal autoantigens may provide a means to earlier identification of people at 
risk for developing neuropathy and allow for development of strategies for prevention.
In these studies, we used an adrenergic clone of a murine neuroblastoma tumor, 
N1E-115 (NB) as an autonomic neuron model to investigate the humoral factors in sera of 
diabetic patients with neuropathy on neuronal cell growth and differentiation. 
Neuroblastoma is a neoplasm of the adrenal medulla and components of the peripheral 
autonomic nervous system. They are widely used as a model for neuronal research, 
because they exhibit properties similar to differentiated sympathetic neurons such as neurite 
outgrowth, synthesis of neuropeptides or neurotransmitters and expression of receptors for
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pharmacological agents (Sonnenfeld, 1982). Such a neuronal cell model might allow early 
prediction and prevention of diabetic neuropathy. It could also be a useful model to study 
the mechanism of neuronal death, autoimmune pathogenesis and possible immunotherapy as 
well as the protective effects of neurotrophic factors or other new drugs on diabetic 
neuropathy.
i
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CHAPTER II. THE HUMORAL EFFECT OF DIABETIC PATIENTS’ SERA 
ON NIE-II5 CELL PROLIFERATION AND DIFFERENTIATION
Previous evidence showing that autoantibodies to autonomic nerve tissue 
components had a higher frequency in neuropathic patients with diabetes than in diabetic 
control subjects with disease o f similar duration indicated that neuronal tissue 
autoantibodies have a role in the development o f symptomatic autonomic neuropathy 
(Brown et al., 1989). However, it was unclear whether these autoantibodies can directly 
cause neuronal tissue damage or whether they were only a secondary manifestation, 
because of the exposure of autoantigen after neuronal tissue damage. Also, what was the 
possible mechanism by which these antibodies or other humoral factors besides 
immunoglobulins could cause neuronal death? To answer these questions, the humoral 
effect o f diabetic patient sera (IDDM, NIDDM) and control subject sera on N IE -115 
neuroblastoma cell growth and differentiation was investigated.
2.1. Diabetic patients' sera collection and N1E-115 neuroblastoma ceil line 
as a model of sympathetic neurons
Serum was collected from patients in three categories: control subjects, patients 
with insulin-dependent diabetes mellitus (IDDM) and patients with non-insulin-dependent 
diabetes mellitus (NIDDM) (Table. 1). Patients with IDDM, or type I diabetes, were 
separated into groups with neuropathy and without neuropathy. Diabetic neuropathy was 
established by the presence o f symptoms, signs, and quantitative electrophysiology, 
electromyography or other neuropathy tests, according to the recommendation o f the 
American Diabetes Association and the American Academy of Neurology (1988).
The sex distribution between groups was well matched. Because of the nature o f 
the disorders, patients with NIDDM were significantly heavier and older
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Table 1. Sera were collected from healthy controls and patients with either NIDDM or 
IDDM. IDDM patients were further separated into groups with neuropathy or without 
neuropathy. The serum glucose level, H bA lc level, duration of diabetes as well as 
cholesterol and lipid levels were determined by group. The age and weight o f NIDDM 
patients was significantly higher (*, p<0.05) than any of the groups. The serum glucose 
and H bA lc measures were elevated in the diabetic groups compared to controls.
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Parameter Control Type 1 diabetes Type 1 diabetes Type 2 diabetes
Neuropathy 0 /1 1 9/9 0/7 9/10
Sex 7F/4M 6F/3M 3F/4M 6F/4M
Age (yr) 41.2*2.6 36.6*3.1 37.6*3.1 62.1*3.7*
Weight (kg) 68.1*6.1 70.7*4.9 78.1*3.1 87.7*5.2*
Glucose (mg/dl) 89 .4 * 1 .3 226*37.6 128*29.3 217*22.0*
Cholesterol (mg/dl) 222.4*18.3 220*18.3 221*19.3 230*19.3
Triglycerides (mg/dl) 97.3*15.4 100*14.0 87*11.3 183*32.4
HDL-C (mg/dl) 61.2*4.9 64*4.0 59*2.5 50*4.9
LDL-C (mg/dl) 141.7*17.4 144*22.2 145*18.4 147*17.1
HbA ic(%) Range [3.4-6.1 ] 9 .2*0.6 7.2*0.3 8.5*0.7
Duration o f Disease (yr) NA 19.7*2.86 15.3*3.4 10.4*2.4
 ____________
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than the other groups. Serum glucose level and HbA lc in both EDDM and NIDDM 
patients were significantly higher than the normal range. The duration of diabetes was 
slightly longer in both IDDM groups than the NIDDM patients, but did not reach statistical 
significance. Cholesterol and lipid levels did not differ between groups. None of the 
subjects had clinical nephropathy. Serum urea and creatinine measurements were normal.
The N1E-115 neuroblastoma cell line was an adrenergic cell clone derived from the 
C1300 murine neuroblastoma tumor (Amano, 1972). This cell line had the capacity to 
develop the characteristics of adrenergic neurons when maintained in cell culture, and 
therefore was representative of sympathetic autonomic neurons. These cells could be 
induced to differentiate and extend neurites by removal of serum from the media.
2.2. The humoral effect of diabetic patients' sera (IDDM, NIDDM) and 
control sera on neuronal cell proliferation
Neuronal cell growth tests were performed by growing flasks of N1E-115 cells to 
confluence, lifting the cells with Pucks' D1 solution, and subculturing at 105 cells per 
35mm2 dish. The cultures were split into four groups (IDDM, NIDDM, control and FBS) 
of four plates each, cultured in DMEM (4,500mg/L D-glucose) supplemented with 10% 
human serum from each group. Each day for 4 consecutive days the cells from one plate in 
each group were lifted and the number of viable cells in each dish was determined using 
trypan blue exclusion criteria. The viable cell counts were taken over a 5-day period 
(including the day o f  plating), and the growth curves for each group were established.
Figure 1 shows the mean viable cell number in cultures treated with sera from 5 
groups during Five days culture period. Control group included 9 individuals; IDDM 
without neuropathy included 7 individuals; IDDM with neuropathy included 6 individuals; 
NIDDM included 10 individuals and 9 with neuropathy. The results show that N IE -115 
neuroblastoma cells grow rapidly in regular 10% FBS-containing DMEM media (F ig .l; 
Fig.2-a). The viable cell numbers were reduced when cells were grown in media containing
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Figure 1. Mean growth curves for N1E-115 NB cells in DMEM media with 10% serum 
from different population groups. The N1E-115 cell cultures were exposed to 10% fetal 
bovine serum (FBS) or control sera, sera from IDDM patients with and without 
neuropathy or NIDDM patients' sera with neuropathy for 5 days, the viable cells were 
counted by trypan blue exclusion criteria and expressed as mean±SEM. Cell growth was 
significantly inhibited (*p< 0.05) by sera from IDDM patients with neuropathy compared 
to cells grown in sera from control, NIDDM, and IDDM patients without neuropathy on 
days 4-5 o f culture. Viable cell number was determined using trypan blue exclusion 
criteria. The control group included 9 individuals; IDDM without neuropathy included 7 
individuals; IDDM with neuropathy included 6 individuals; NIDDM included 10 
individuals. Statistical analysis was performed by analysis of variance and Wilcoxon 
rank sum test.
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Figure 2. Representative photomicrographs of N1E-115 NB cell growth in DMEM 
media with 10% serum from different groups: (A). 10% FBS; (B). 10% serum from a 
control subject; (C). 10% serum from an IDDM patient with neuropathy; (D). 10% serum 
from an NIDDM patient with neuropathy. N1E-115 cells in A, B and D showed the 
normal cell appearance and most cells were health, while those treated with IDDM serum 
showed cytotoxic effects indicated by cell shrinkage, lifting from attachment and cell 
death (C).
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10% human serum. There was no statistically significant difference between the healthy 
control group, NIDDM with neuropathy and IDDM without neuropathy. In contrast, 
viable cell numbers in cultures treated with serum from the IDDM patients with neuropathy 
were significantly lower than in the FBS cultures by day 2 (p<0.05) and cultures with 
NIDDM and IDDM serum without neuropathy by day 4 and 5 (p<0.05). In 3 of the 6 
cases, IDDM serum associated with neuropathy appeared to cause total cell death within 3 
days. However, this also occurred in response to one serum sample from a IDDM patient 
without neuropathy.
2.3. The humoral effect of diabetic patients' sera (IDDM, NIDDM) and
control sera on neuronal cell differentiation
N IE -115 cells were subcultured into 12-well culture plates for 2 days in DMEM 
media supplemented with 10% FBS. The cultures were then exposed to individual serum 
from each group used in the cell growth studies for 24 hr. The serum was then removed 
from the culture media and the cells grown in serum-free DMEM for another 24 hr to 
induce differentiation. The differentiated cell was defined as one that had at least one 
neurite extended from the cell body by more than one cell diameter. Two hundred cells 
from each well were evaluated under phase contrast microscopy and the differentiation rate 
(%) and length of neurites were determined.
The results of the study show that the sera from the IDDM patients with neuropathy 
group significantly (p<0.05) inhibited neuroblastoma cell differentiation after 24 hr
(differentiation rate = 18.7%) compared to NIDDM (30.0%) and control (42.4%) groups
(Fig. 3, Fig. 4). However, once the cells were induced to differentiate, the neurite length 
extended did not show a significant difference after exposure to serum from the different 
groups (Fig. 5.).
2.4. The Effect of IDDM sera pre-absorbed by N1E-II5 cells and mouse
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liver acetone powder on cell proliferation.
To determine whether the inhibition of cell proliferation was due to the presence of 
a cytotoxic factor in the serum, or the absence of a supporting factor required for cell 
survival, human sera from 3 subject groups were pre-absorbed by N IE -115 neuroblastoma 
cells (Fig. 6) and mouse liver acetone powder. Aliquots of sera were pre-incubated with 
106 neuroblastoma cells or 1 mg of mouse liver acetone powder at 37°C for 20 min. After 
centrifugation for 10 min at 3000xg, the supernatant sera were applied to neuroblastoma 
cell cultures as a 10% concentration in DMEM for 24 hr and compared with cell cultures in 
10% non-absorbed serum media. The growth inhibition of IDDM serum was totally 
reversed by pre-absorption to neuroblastoma cells but not mouse liver acetone powder pre- 
absorption. The results demonstrated that cell growth inhibition was caused by some 
'cytotoxic factor' in IDDM serum that could be pre-absorbed by neuroblastoma cells but 
not other mouse tissue extracts prepared with organic solvents. It also indicates that the cell 
growth inhibition or death was not only caused by a deficiency o f required factors in EDDM 
serum (Fig. 7).
Summary
Using N1E-115 neuroblastoma (NB) cells as an adrenergic neuronal model, we 
found that the serum from EDDM patients with neuropathy had greater effects and more 
frequently inhibited neuronal cell growth and differentiation than control sera and sera from 
non-neuropathic IDDM. In some cases, individual IDDM sera caused neuronal death. This 
inhibiting or neurotoxic effect of IDDM serum could be partially reversed by NB cell pre- 
absorption, which suggested that the cytotoxic effect was caused by a cytotoxic factor in 
the serum, although we have not excluded that neurotrophic factors in the serum may also 
have some effect. This cytotoxic effect could not be removed by preabsorption with mouse 
liver powder prepared with an organic solvent, indicating that it could be a tissue specific 
effect or that the antigen was extracted by organic solvents.
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Figure 3. N1E-115 NB cell differentiation rate after exposure to individual serum from 
different groups. N1E-115 neuroblastoma cells were exposed to 10% serum from 
different population groups for 24 hr and then induced to differentiate by removing serum 
from the medium for 24 hr. The cells extending neurites were counted, expressed as a 
percent o f total cells and compared among different groups. There was a significant 
inhibition (*p<0.05) in the percentage of cells extending neurites in response to IDDM 
serum, but not in response to NIDDM serum. There were 9 individuals in control group, 
10 individuals in IDDM group and 10 individuals in NIDDM group tested.
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Figure 4. Representative photomicrographs o f morphology of differentiated NB cells 
after treatment with different serum groups. N1E-115 neuroblastoma cells treated with 
10% serum from different population groups for 48 hr and then cultured in serum-free 
medium to induce differentiation: (A) Control; (B) IDDM; (C) NIDDM. Serum from an 
IDDM patient with neuropathy (B) inhibited neurite extension.
€    _
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F igure  5. the neurite length after exposure to sera from  different groups. N1E-115 
neuroblastom a cells were cultured in DM EM  media containing 10% serum from 
individuals of different population groups for 48 hr and then cultured in serum free media 
to induce neurite extension (differentiation). The length of the longest neurite on each 
evaluated cell was measured under m icroscopy. At least 20 differentiated cells were 
measured from each individual. There were 9 individuals in control group, 10 individuals 
in IDDM  group and 10 individuals in NIDDM  group evaluated. The results show that 
there was no significant difference among different groups.
i
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.


































Figure 6. The principle of immune pre-absorption. For pre-absorption studies, 1()6NB cells were collected and 
incubated with IDDM serum, which had shown a cytotoxic effect on NB cell, at 37°C for 30 min. The cells were 
precipitated, and the supernatant serum was added to the NB cell culture to examine the effect on cell growth and 
compare with serum before absorption. The absorbed NB cells were lysed and the protein components were collected 
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Figure 7. Photomicrographs of the effect of IDDM sera pre-absorbed by NB cells on cell 
growth. N1E-115 neuroblastoma cell cultures exposed to serum from a patient with 
IDDM before or after pre-absorption by neuroblastoma cells, (a) The IDDM patient 
serum inhibited NB cell growth and caused cell death, (b) The same IDDM patient serum 
absorbed by NB cells showed a complete reversal of the cytotoxic effect. These studies 
demonstrated the presence of a cytotoxic factor in the IDDM serum.
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CHAPTER III. IDENTIFY THE NEURONAL TOXIC FACTORS IN THE 
SERA OF IDDM PATIENTS WITH NEUROPATHY
In the previous studies, we found that there was a cytotoxic factor in IDDM patients 
with neuropathy, but not in sera from the NIDDM group and control group. Because there 
was a different effect of IDDM and NIDDM sera on proliferation and differentiation, this 
suggested a difference in pathogenesis of neuropathy between IDDM and NIDDM groups. 
Based on this and previous studies by other investigators, an autoimmune-related humoral 
factor, such as autoantibodies, was considered in mediating the neuronal death effect of 
IDDM sera. Here, we investigated whether this cytotoxic effect was mediated by an 
immunoglobulin and/or other humoral factors.
3.1. Effect of IDDM sera pre-absorbed by protein A on cell growth.
Affi-Gel protein A agarose (Bio-Rad, Inc., Richmond, CA) was washed with PBS 
and added to the test serum at a 2:1 (v/v) dilution. After incubation for 30 min in a 37°C 
water bath, the mix was centrifuged at 10,000xg for 30 min to precipitate the protein A gel. 
Identical untreated sera were tested in parallel with the protein A precipitated sera for both 
control and IDDM groups. The groups tested included 6 IDDM patients with neuropathy 
or 6 control subjects. The results showed that precipitation of immunoglobulin (Ig) from 
control sera had little effect on cell growth (8.6±1.3 x 103 cells before precipitation and 
9.4±1.8 x 105 cells after Ig precipitation). In contrast, depletion of Ig from IDDM serum 
significantly (p<0.05, one way ANOVA) improved cell growth (3.7±1.5 x 103 cells before 
precipitation and 8.0±1.2 xlO5 cells after precipitation), There was an 3/4 recovery from 
57% inhibition before protein A treatment to 15.2% inhibition after protein A treatment, 
indicating that the protein A-agarose was able to remove about 75% of the cytotoxic effect 
in IDDM serum (Fig. 8).
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Figure 8. The effect o f protein A precipitated sera on N1E-115 cell growth. Sera were 
precipitated with protein A from 6 IDDM and 6 control subjects. Equal numbers of N1E- 
115 cells were cultured in DMEM media supplemented with 10% of one of four test sera: 
control serum, IDDM serum, protein A-absorbed control serum or protein A-absorbed 
IDDM serum. After 72 hr the viable cells were counted and the mean for each group was 
determined. There was a significant reduction (*p<0.05) in cell number in cultures 
treated with IDDM sera compared to cultures treated with control sera. However, after 
protein A absorption, IDDM sera were able to support cell growth similarly to untreated 
control sera. There was a 73.3% recovery from inhibition before protein A treatment, 
indicating that the protein A-agarose was able to remove the cytotoxic factor in IDDM 
serum in large portion. There was no significant change in the ability of control sera to 
support cell growth after protein A absorption.
4 - __________________
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3.2. Effects of immunoglobulin fractions extracted from diabetic sera 
(IDDM, NIDDM) and control sera on cell growth.
Immunoglobulin was precipitated from sera of 10 subjects from each of the IDDM, 
NIDDM and control groups. Immunoglobulin was precipitated from the test sera by 
gradually adding saturated (N H ^ S C ^  to the serum to a final concentration of 40%, and
the slurry was stirred at 4°C overnight. The solution was centrifuged at 10,000xg for 30
min. The supernatant was removed and the pellet was resuspended in pH 7.4 PBS and 
dialyzed with 3 changes of 10 volumes of PBS to remove (N H 4) ,S 0 4. Immunoglobulin
fractions isolated from serum from each subject were tested separately in neuroblastoma 
cell cultures, at a concentration of 10% serum equivalents in DMEM plus 10% pooled 
human serum (Gibco, Grand Island, NY). Viable cells were counted for 5 consecutive 
days to determine the effect of the Ig fractions on cell growth. When the immunoglobulins 
precipitated were applied to the cell culture media in the absence o f serum, the cells did not 
grow well because of the lack of serum and began differentiating. However, when the Ig 
isolated from IDDM serum was added to medium containing 10% of commercial pooled 
human serum (Gibco, Grand Island, NY), cell growth was significantly (one way 
ANOVA, p< 0.01) inhibited by day 4 and 5 of culture, compared to the growth in the 
presence of Ig precipitated from control serum (Fig. 9). The growth of cells in media with 
Ig from the control group sera did not differ from that of media containing 10% pooled 
serum alone (Fig. 9).
3.3. Effects of heat inactivated IDDM and control sera on cell growth.
Test sera from IDDM and the healthy control groups were heated in a 56°C water 
bath for 30 min to inactivate the complement to test the effect on neuroblastoma cell 
growth. Heat inactivated serum was then added to the DMEM media and incubated for 72 
hr as described before. Non-heated serum was tested in parallel with the heated
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Figure 9. The effects of immunoglobulin fractions extracted from different groups on 
N1E-115 cell growth. The effect of immunoglobulin-containing fractions precipitated 
from serum o f 10 subjects in each of the IDDM, NIDDM and control groups on NB cell 
growth, expressed as mean±SEM. Cells were grown in DMEM media supplemented 
with 10% of a pooled normal human serum. Immunoglobulin isolated from sera in the 
test groups were added to cell cultures for 5 days. The viable cell number was counted by 
trypan blue exclusion criteria. There was a significant (*p<0.05) reduction in cell 
numbers in cultures treated with Ig isolated from IDDM sera by day 5 compared with 
control and NIDDM groups.
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Figure 10. Effects o f IDDM and control sera treated by heat inactivqation on N1E-115 
cell growth. Equal numbers of N1E-115 NB cells were cultured in DMEM media 
supplemented with 10% of test sera from 4 different groups: 6 control sera, 6 IDDM sera, 
and the same sera heat inactivated (56°C for 30 min). After 72hr culture the viable cells 
were counted. The cytotoxic effect of IDDM sera was reversed by heat inactivation. 
There was a 66.2% recovery from cytotoxicity (48.5% inhibition before heat treatment 
and 16.4% inhibition after heat treatment). Paired t-test showed statistical significance 
(p< 0.05). There was no significant difference before and after heat treatment in the 
control group.
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counterparts in all studies. The results indicated that heat treatment of control serum had 
little effect on cell growth compared to that of untreated serum. In contrast, for IDDM 
serum that had cytotoxic effects on cell proliferation, heat inactivation significantly 
(p<0.05, paired t-test) reversed the inhibiting effect on the cells in all cases (Fig. 10), with 
a 2/3 recovery of the cytotoxic serum effect (48.5% inhibition before heat treatment and 
16.4% inhibition after heat treatment).
3.4. Identification o f the factor in IDDM serum against N1E-115 cells by 
immunocytochemistry
A number of autoantigens have been proposed as candidates for the targeting of 
autoimmune immunoglobulin in diabetic neuropathy, including glutamic acid decarboxylase 
(GAD), gangliosides and phospholipids. Because GAD is cytoplasmic in neuronal cells 
and gangliosides and phospholipids are membrane components, we felt that identification 
of the topography of the antigens recognized would be helpful. The IDDM and control sera 
were tested for binding to the surface or cytoplasm of the neuroblastoma cells by 
immunocytochemistry. Anti-GAD antibodies, including anti-carboxy terminal of GAD-65, 
anti-amino terminal of GAD-65 and anti-GAD 67, all were provided by Dr. Ake Lemmark 
(Karolinska Institutes, Stockholm, Sweden). Neuroblastoma cells were plated at I04 cells 
in 35mm2 tissue culture dishes on sterile coverslips and grown for 2 days. The cells were 
fixed in 4% paraformaldehyde in PBS for 60 min, blocked by 10% normal goat serum in 
PBS for 30 min, incubated with a 1:100 dilution of test human serum for 90 min, and 
finally exposed to a fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG 
secondary antibody (Sigma Chemical Co., St. Louis, MO) for 60 min. After 
immunostaining, the cells were mounted on slides using o-phenylenediamine (lm g x m f^) 
in 90% glycerol and examined by fluorescence microscopy. To examine cytoplasmic 
immunostaining, the cells were permeabilized after fixation by immersion in acetone for 7 
min prior to the addition o f 10% goat serum.
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Figure 11. Indirect immunofluorescence showing the IgG binding pattern od IDDM 
serum on N1E-115 cells (1). Indirect immunofluorecence (IF) was performed on N1E- 
115 cells using individual serum from different groups as primary antibody and FITC- 
Iabeled anti-human IgG as secondary antibody. (A) Representative photomicrograph of 
IF with IDDM serum which induced cell death as primary antibody on N1E-115 cells 
fixed on cover slide. (B) Representative photomicrograph of IF with IDDM serum as 
primary antibody on differentiated cells. (C) Representative photomicrograph of IF with 
NIDDM serum as the primary antibody. (D) IF with control serum as the primary 
antibody. The IF with IDDM serum treated slides showed a fluorescent ring, indicating 
binding at the cell membrane (arrows), but not in cells treated with any of the other sera.
A ___  . .
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 3. Identify the Neuronal Toxic Factors 48
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 12. Indirect immunofluorescence showing the IgG binding pattern o f IDDM 
serum on N1E-I15 cells (2). Indirect immunofluorecence was performed on N1E-115 
cells using IDDM (A), or control serum (B) as primary antibody and FITC-labeled anti- 
human IgG as secondary antibody and observed at high magnification. There was light 
diffuse fluorescent staining in cells exposed to control serum (B). In contrast, cells 
exposed to IDDM serum showed a specific bright halo of fluorescence (A, arrows), 
indicating the recognition of a cell surface antigen by immunoglobulin IgG in IDDM 
serum.
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The results showed a characteristic cell surface binding pattern with a bright rim of 
immunofluorescence when cells were labeled with serum from IDDM patients with 
neuropathy (Fig. 11-A; Fig. 12-A), indicating specific recognition of a membrane antigen. 
This pattern was not seen in cells treated with control serum (Fig. 11-D, Fig. 12-B) or 
NIDDM serum (Fig. 11-C). Three monoclonal anti-GAD antibodies only show weak 
cytoplasmic binding and no cell surface binding ( picture not shown).
Summary
The properties of the cytotoxic factor present in EDDM serum were examined. 
These studies indicate that the factor was likely to be an immunoglobulin. The neurotoxic 
effect could be reduced by 75% by protein A precipitation. The cytotoxic factor was 
present in the immunoglobulin containing fraction precipitated from EDDM patients' sera, 
evidenced by the inhibition of growth of cells treated with immunoglobulins extracted from 
the IDDM sera. Indirect immunofluorescence using IDDM sera showing cytotoxicity as 
primary antibody and FITC labeled anti-human IgG as secondary revealed a specific cell- 
surface IgG binding pattern, further supporting the hypothesis that there was 
immunoglobulin IgG binding to the cell surface. Moreover, the cytotoxic effect was 
reversed about 2/3 by heat inactivation, suggesting the possible involvement of 
complement, but not excluding other heat-sensitive factors.
i  ___  _
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CHAPTER IV. STUDIES OF THE MECHANISM OF NEURONAL DEATH 
CAUSED BY SERUM OF IDDM PATIENTS
There are two forms of cell death with very different characteristics, i.e., necrosis 
and apoptosis. These differ both morphologically and biochemically. Apoptosis is an 
active process of neuronal cell death with specific, defining morphologic and molecular 
features, such as cell shrinkage with preservation of organelles, membrane blebbing, 
condensation of cytoplasm, compacting of chromatin, fragmentation of DNA into 
oligomers, detachment from surrounding cells and the formation of apoptotic bodies 
(Carson, 1993). Necrosis is an event with passive cell swelling, membrane lysis and rapid 
collapse of internal homeostasis. Apoptosis as a mechanism of cell death has been 
suggested in many neurodegenerative diseases.
In previous studies, we found that serum from EDDM patients inhibited N IE -115 
cell growth and differentiation as well as caused cell death in some cases. In attempting to 
define the mechanism and events leading to neuronal death induced by EDDM patient 
serum, we examined the morphologic, biochemical and genomic DNA change and 
intracellular Ca2+ change of N1E-115 cells after exposure to EDDM serum. Further, we 
tested one regulator of apoptosis, Fas/APO-1, as a mediator of the apoptotic effects 
observed in response to IDDM sera.
4.1. Morphology change of NIE-115 cells after exposure to IDDM serum
We previously observed that some sera of IDDM patients with neuropathy induce 
NIE-115 neuroblastoma cell death as early as 4 hr. Furthermore, after exposure to sera 
from EDDM patients, the morphological changes of NB cells under phase contrast 
microscopy showed eccentric cytoplasmic condensation, cell shrinkage and lifting from 
attachment. Some cells had an intact membrane ballooned around the condensed cytoplasm,
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Figure 13. Morphology change of NIE-115 cells after exposure to IDDM serum. N IE - 
115 neuroblastoma cells were split and grown in DMEM medium with 10% serum from 
control subjects (A) or IDDM patients (B). After exposure to serum from an IDDM 
patient, the morphological changes o f NB cells under phase contrast microscopy show 
eccentric cytoplasmic condensation, cell shrinkage and lifting from attachment (all 
indicating an apoptotic cell death). Some cells have intact cell membrane around 
condensed cytoplasm (arrow).
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all suggesting apoptotic cell death (Fig. 13). The viable cell number was reduced 
significantly as counted with trypan blue exclusion criteria, indicating some manner of cell 
removal or death. It should be noted that the number of viable cells might be overestimated 
by this procedure, due to the intact cell membranes of apoptotic cells, which would also 
exclude trypan blue and could be counted as viable.
4.2. Intracellular calcium change induced by IDDM serum
One of the early cellular changes described with apoptosis is a rise in intracellular 
Ca2+. To measure the changes of intracellular free calcium in response to IDDM serum, 
106NB cells/ml were loaded with the fluorescent intracellular calcium indicator, Fura-2 
(5uM final conc.), mixed with pluronic acid (0.02%) to facilitate entry into the cell. After 
incubation at 37°C for 60 min, extracellular dye was removed by centrifugation and the NB 
cells were resuspended in PBS buffer with 1% bovine serum albumin. An aliquot of cells 
was added to a cuvette, which was constantly stirred, and measurements were taken by 
alternate excitement with 340nm and 380nm light and emission read at 540nm. The 
sensitivity of Fura-2 loaded NB was checked with histamine and calibrated for minimum 
and maximum fluorescence during each experiment. Serum from IDDM, NIDDM and 
control subjects was added directly to the cuvette, individually at 15% final concentration. 
The emission was recorded for 5-10 min and then analyzed and graphed using the software 
SPEX-DM 3000 according to the equations of Grynkiewicz et al, (1985). Results showed 
that five of the eight IDDM sera caused a sustained increase of intracellular calcium 
concentration, starting within 10 seconds after the initial exposure to IDDM serum and 
continuing to increase at least up to 10 min (Fig. 14; Fig. 15. 1-4), while with most control 
sera (4/5), there was an early peak and then return to base line (Fig. 15. 5-6). There was a 
significant (Chi-square, p< 0.05) difference in the frequency of increased intracellular Ca2+ 
in response to sera from the IDDM and control groups. The early transient peak was 
considered to be an artifact of adding serum. These results suggested that the elevation of
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Figure 14. Intracellular calcium changes induced by IDDM serum (1). Typical patterns 
of cytosolic free calcium change in response to IDDM and control serum in NB cells 
loaded with the intracellular calcium indicator, Fura-2 are shown in this and figure 16. 
Results showed that five of the eight IDDM sera caused a sustained increase of 
intracellular calcium concentration, starting within 10 seconds after the initial exposure to 
IDDM serum and continuing to increase at least up to 10 min, while with most control 
sera (4/5), there was an early transient peak and then concentrations returned to baseline. 
This was a significant (Chi-square, p< 0.05) difference in the frequency of increased 
intracellular Ca2+ in response to serum from the IDDM and control groups.
l
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F igu re  15. In tracellu lar calcium changes induced by IDDM serum (2). The 
representative changes o f cytosolic free calcium in response to IDDM serum (1-4) and 
control serum (5-6) in NB cells loaded with the intracellular calcium indicator, Fura-2 
were shown. IDDM  sera caused a sustained increase of intracellular calcium  
concentration, starting 10 seconds after initial exposure to IDDM serum and continuing to 
increase up to 10 min (1-4), while with control sera, there was an early peak and then a 
return to base line (6) or a sustained reduction in intracellular calcium (5).
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intracellular calcium may play a role in the process of cell death by apoptosis.
4.3. Examine genomic DNA fragmentation of NIE-115 ceils after exposure 
to IDDM serum
IDDM sera showing cytotoxicity to neuroblastoma cells were added to 
neuroblastoma cell cultures as 15% in DMEM. Suspended and attached cells were 
collected separately at 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr after exposure to IDDM serum. 
The genomic DNA from cells collected at each time point was isolated with a gentle process 
using a Micro TurboGen kit (Invitrogen, San Diego). The cells were Iysed with lysing 
buffer and RNase solution from the kit. After the lysates were incubated at 65°C for 5 
minutes, the protein fraction was precipitated by adding chloroform and separated from the 
aqueous layer containing DNA by centrifugation. The DNA was precipitated, washed and 
quantitated, and finally resuspended in pH 8.0 TE (Tris-EDTA) buffer. The purified 
genomic DNA was separated by electrophoresis on 1% agarose gel and stained with 
ethidium bromide. The gel was examined under ultraviolet illumination to check for the 
DNA pattern. The genomic DNA of cells treated with control serum was purified and run 
on gel electrophoresis in parallel. Results showed that a DNA fragmentation ladder, a 
marker o f apoptotic cell death, was revealed from suspended cells (Fig. 16, A lanes) as 
early as 4 hr after NB cell exposure to cytotoxic EDDM serum. The DNA fragmentation 
patterns and time of appearance were similar for the IDDM sera tested (F ig.l6-A  and B, 
lanes A). The cells retaining attachment show no pattern of DNA fragmentation (Fig. 16-A 
and B, B lanes) reflecting a non-apoptotic state.
4.4. Studies of apoptosis-related proteins (Fas, p75) expression in NIE-  
115 NB cells
Indirect immunofluorescence (IF)
IF was performed to examine the expression of the apoptosis-related proteins
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Figure 16. Cellular DNA fragmentation ladder of N IE-115 cells induced by IDDM 
serum. IDDM serum showing cytotoxicity to neuroblastoma cell was added to a set of 
neuroblastoma cell cultures as 15% in DMEM. Suspended and attached ceils were 
collected separately at 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr. The genomic DNA was 
isolated at each time point and separated by electrophoresis on a 1% agarose gel. A lanes 
were DNA extracted from  suspended cells and B lanes were DNA extracted from 
attached cells. A DNA fragmentation ladder, characteristic of apoptotic cell death, was 
revealed in cells that have lost attachment as early as 4 hr after NB cell exposure to 
cytotoxic IDDM serum but not with control serum. The DNA fragmentation ladder was 
shown in suspended cells but not attached cells. The DNA fragmentation pattern and time 
course are similar with two individual IDDM sera.
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Figure 17. Indirect immunofluorescence detecting Fas expression and changes in N1E- 
115 cells. Photomicrographs of indirect immunofluorescence using hamster anti-mouse 
Fas monoclonal antibody (mAb) (MBL RK8) as primary antibody and FITC labeled anti­
mouse IgG secondary antibody are shown. The results demonstrate that Fas is expressed 
on the NIE-115 NB cell surface (a) as well as on differentiated NIE-115 NB cells (b, 
arrows). The surface staining pattern is totally blocked by IDDM serum (c), suggesting 
that Fas might be one of the surface antigens recognized by immunoglobulin from IDDM 
serum (c). Fas staining on NB cells showed a cluster pattern after culture with IDDM 
serum 24 hr prior to fixation (d). The residual yellow fluorescence is autofluorescence 
from the cell nuclei.
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(Fas, p75> bcl-2, p53) and their possible change in N1E-115 cells after exposure to IDDM 
serum. p75 and bcl-2 were expressed weakly on N1E-115 cells (data not shown), while 
Fas was strongly expressed on the cell surface (Fig. 17). Because Fas was known as a 
surface receptor mediating apoptotic cell death, we hypothesized that IDDM serum might 
induce cell death through a death signal from Fas. Whether the toxic factor in IDDM serum 
might block anti-Fas antibody binding to the cell surface was also examined. The 
procedure of immunofluorescence was performed as described before. Briefly, N1E-115 
cells were plated at 104 cells in 35mm2 tissue culture dishes on sterile coverslips and grown
for 2 days. The cells were fixed in 4% paraformaldehyde in PBS for 60 min, blocked by 
10% mouse serum in PBS for 30 min, incubated with a 1:100 dilution of hamster anti­
mouse Fas (MBL, RK8) serum for 60 min, washed 3 times with PBS and exposed to 
secondary fluorescent isothiocyanate (FITC)-labeled mouse anti-hamster IgG secondary 
antibody (Pharmingen, San Diego) for 30 min. After immunostaining, the cells were 
mounted on slides using o-phenylenediamine (lm g x ml'*) in 90% glycerol and examined 
by fluorescence microscopy. To examine whether IDDM serum blocked anti-Fas mAb 
binding, fixed NB cells were first exposed to IDDM serum for 30 min then to the anti-Fas 
mAb and FITC-Iabeled secondary antibody. To examine the change of Fas expression on 
NB cells after culture with IDDM serum, the NB cells were cultured in DMEM containing 
10% IDDM serum for 24 hr, then IF was performed.
The immunofluorecence studies revealed that Fas was expressed on the N1E-115 
NB cell surface in a characteristic non-homogeneous staining pattern (Fig.l7-a). Fas was 
also expressed on differentiated N1E-115 NB cells, which were induced to differentiate by 
culture in serum free media for 24 hr (Fig. 17-b). The surface staining pattern with anti- 
Fas mAb was completely blocked by cytotoxic IDDM serum, suggesting that Fas might be 
one of the surface antigens recognized by IDDM serum (Fig. 17-c). After NB were 
cultured in DMEM media with 10% IDDM serum for 24 hr, Fas staining on NB cell 
showed a clustering pattern, indicating possible cross-linking by antibody or soluble Fas
*
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ligand in IDDM serum, a prerequisite for Fas activation and apoptosis.
Expression o f p75 was also examined by IF in N1E-I15 NB cells. For p75 
detection, anti-p75 monoclonal antibody was obtained from Boehringer Mannheim 
Biochemica (Indianapolis, IN). However, there was only a weak fluorescence signal 
observed (results not shown). p53 expression was abundant in the cell nucleus and 
perinuclear cytoplasmic region with IF (results not shown), but because of the cytoplasmic 
localization of this nuclear protein, the significance was uncertain. Because N1E-115 cell is 
a tumor cell line, the p53 could be mutated causing inactivation and dislocated from of the 
nuclear to the cytoplasm region. Bcl-2 expression was not detectable in this cell line either 
in proliferating or differentiating stages.
N IE-115 cell membrane protein extraction, immunoprecipitation and 
Western blotting
Protein chemistry techniques were employed to confirm the presence of Fas in NB 
cells. NB cells (107) were lysed by nitrogen cavitation (PARR Instrument Company, 
Moline, IL) in PBS. Cell membrane and cytosol fractions were separated by gradient 
centrifugation. The tissue homogenate was first centrifuged at 500 x g to remove crude 
nuclear material, then 10,000 x g to remove mitochondria and 100,000 x g for 60 min to 
get the microsomal fraction containing cell membranes. Membrane protein fractions were 
solubilized with 1% Triton-XlOO detergent in buffer containing 150mM NaCl, lOmM Tris 
pH7.4, ImM EDTA, Im M  EGTA, 0.2mM sodium vanadate and 0.5%NP-40 (Tiruppathi, 
1986) and the protein content was quantitated with a Micro BCA Protein Assay kit (Pierce 
Co., IL). Fifty pi of total lysate containing 100 pg of membrane protein fractions were 
mixed with 10 pi of anti-Fas mAb (MBL, RK8 clone about 5 pg) at 4°C for 30 min 
followed by 50 pi of 10% protein A beads for 30 min. The protein A beads were spun 
down and washed with PBS for 3 times, then the pellet was resuspend in electrophoresis 
sample buffer, and boiled for 5 minutes. The supernatant was loaded onto a 12% SDS-
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polyacrylamide gel. After Coomassie blue staining, a major protein band at mouse Fas 
MW 40kDa was revealed (Fig. 18-A).
For Western blotting, the NB cell membrane proteins and whole cell homogenates 
were solubilized with 1% Triton-XlOO detergent in buffer containing 150mM NaCl, lOmM 
Tris pH7.4, ImM  EDTA, ImM EGTA, 0.2mM sodium vanadate and 0.5% NP-40 for 30 
min, and the protein content was quantitated with the Micro BCA Protein Assay kit (Pierce 
Co., IL). Fifty p.1 total lysate containing 100 pg membrane protein fractions were mixed 
with 100 pi o f IDDM serum at 4°C for 30 min followed by 50 pi of protein A beads for 30 
min. The protein A beads were centrifuged and washed with PBS 3 times, then the pellet 
resuspended in electrophoresis sample buffer and boiled for 5 minutes. The supernatant 
was loaded onto a 12% SDS-polyacrylamide gel and separated by electrophoresis, then 
transferred to PVDF membrane. The membrane was exposed to anti-Fas monoclonal 
antibody (MBL, RK8) at a 1:200 dilution at room temperature (RT) for 30 min and washed 
3 times with PBS, then exposed to a secondary peroxidase-labeled anti-IgG secondary 
antibody at RT for 30 min and developed by enzyme chemiluminescence (ECL) 
(Amersham Life Science, Arlington, IL) with Kodak X-Omat AR5 film (Kodak Co., 
Rochester, NY) (Fig. 18-B). These studies demonstrated that NB cell membrane proteins 
and whole cell proteins immunoprecipitated with 3 individual IDDM sera, separated by 
SDS-polyacrylamide gel electrophoresis and revealed by Western blot with anti-Fas mAb, 
showed Fas protein. The results indicated that Fas could be one of the proteins recognized 
by IDDM serum. However, more studies are needed to demonstrate that anti-Fas antibody 
or Fas ligands are present in IDDM serum and could cause neural cell death.
The effects of Anti-Fas mAb on neuroblastoma cell growth
If N1E-115 cells express Fas, activating anti-Fas mAb may have an inhibiting or 
lethal effect on cell growth in culture. RK8 anti-Fas mAb, which had been shown to 
activate the Fas mechanism in other cells, was added to the N IE -115 cell culture in three
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 18. Immunoprecipitation and western blot o f Fas from N1E-115 cells. 18-A. 
Proteins from the membrane fraction of NB cells were immunoprecipitated with anti-Fas 
mAb and run on SDS polyacrylamide gel, showing a m ajor protein band at 40kDa, the 
mouse Fas molecular weight. F igure 18-B: Proteins from the NB cell membrane and 
whole cell preparations were immunoprecipitated with IDDM serum, separated by SDS- 
PAGE and Western blot performed with anti-Fas mAb. Protein in lanes 1, 2/3 and 4 were 
precipitated by serum from 3 different patients. Lanes 2 and 3 were precipitated with the 
same serum, but performed with whole cell protein or membrane protein as indicated 
(WP - whole cell protein; MP - cell membrane protein). Protein recognized by the anti- 
Fas antibody was precipitated from NB cells by all 3 IDDM sera tested.
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Figure 19. The effects o f anti-Fas mAb on N1E-115 cell growth. To examine the effects 
of anti-Fas mAb on NB cell growth, different doses of anti-Fas mAb (1000 ng/ml, 500 
ng/ml, 100 ng/ml) were added to the N1E-115 cell culture media for 72 hr. The number 
of viable cells was determined by trypan blue exclusion criteria as described before. The 
maximal dose of anti-Fas mAb (1000 ng/ml) had 49.3% inhibition compared with 10% 
FBS control.
d
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doses (100 ng/ml, 500 ng/ml and 1000 ng/ml). Anti-Fas mAb caused the loss of NB cells 
in a dose-dependent manner within 72 hr of culture. The maximal dose of anti-Fas mAb 
(1000 ng/ml) had 43.8% inhibition compared with control (Fig. 19). This observation 
further supported the presence of membrane-bound Fas on NB cells and the possibility that 
anti-Fas antibody in IDDM serum could cause inhibition of cell growth.
Summary
Apoptosis as the possible mechanism of neuronal death induced by IDDM serum 
was examined in the N1E-115 NB cell model. The morphological change of NB cells after 
exposure to IDDM serum exhibited a characteristic apoptotic cell death pattern: cytoplasmic 
condensation, cell shrinkage and lifting. A DNA fragmentation ladder, a marker of 
apoptotic cell death, was evident within 4 hr after exposure to cytotoxic IDDM serum. A 
sustained increase in intracellular calcium concentration was noted in the presence of 5 of 8 
IDDM sera in Fura-2 loaded NB cells, also characteristic of apoptosis. These 
investigations support the hypothesis that the death of NB cells caused by IDDM serum 
occurred by a mechanism of programmed cell death.
Apoptosis-related protein, including Fas and p75 expression in N1E-115 cells was 
examined. Fas was expressed on the NB cell surface in a characteristic non-homogeneous 
distribution, as determined by immunofluorescence staining with anti-mouse Fas mAb. 
The low affinity NGF receptor, p75, was expressed weakly in N1E-115 cells. 
Immunoprecipitation of cell membrane protein with anti-mouse Fas mAb revealed a major 
protein band of MW 40kDa, approximately the size of murine Fas. Cell-surface membrane 
immunofluorescence staining by anti-Fas antibody was completely blocked by IDDM sera 
which were previously shown to induce apoptotic neuronal death. Fas distribution on the 
cell surface was found in a clustering pattern after 24 hr in culture with IDDM serum, 
which may indicate activation of Fas receptors by cross linking with anti-Fas antibody or 
soluble Fas ligand in IDDM serum. Anti-Fas mAb inhibited NB cell growth in a dose
4
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dependent manner. The maximal dose of anti-Fas mAb (1000 ng/ml) had 43.8% inhibition 
compared with control. The studies indicated that Fas could be one of the cell surface 
antigens recognized by humoral factors in IDDM serum. Whether it is the mediator 
inducing apoptotic cell death in response to IDDM serum needs to be confirmed.
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CHAPTER V. SUMMARY AND DISCUSSION 
Summary
The possibility that autoimmune-related humoral factors contribute as a cause of 
diabetic neuropathy was tested by in vitro application of serum from patients with IDDM 
and NIDDM to adrenergic murine neuroblastoma cells in culture. In these studies, we have 
demonstrated that the serum from patients with IDDM and neuropathy could cause inhibition 
of growth and differentiation in N1E-115 neuroblastoma cells and, in some cases, induced 
cell death. The growth-inhibition, or cytotoxic effect, was more prominent in IDDM 
patients with neuropathy but varied in IDDM patients with no neuropathic symptoms. This 
effect was not reproduced in NIDDM patients with neuropathy, suggesting a heterogeneous 
pathogenesis of diabetic neuropathy in these two type of diabetes. The neuronal toxic effect 
of IDDM serum could be abolished by pre-absorption with neuroblastoma cells, indicating 
that the effect was mediated by humoral factors that could bind to neuroblastoma cells.
The identity of the cytotoxic factor in IDDM patients serum was examined. These 
studies indicated that the toxic factor was likely to be an immunoglobulin. The neurotoxic 
effect of IDDM serum could be reduced by protein A pre-absorption (the inhibition was 
reduced by 3/4 comparing before and after protein A treatment). An immunoglobulin- 
containing fraction of IDDM serum exerted the inhibitory effect when pooled human serum 
was added, but not the immunoglobulin containing fraction from NIDDM and control 
groups. The cytotoxic effect was partially reversed by heat inactivation (which reversed the 
inhibiting effect by about 2/3), suggesting the involvement of complement but not excluding 
other heat sensitive factors. However, none of the treatments could totally reverse the 
inhibition, suggesting that multiple mechanisms may be involved.
In our study, examination o f N1E-115 cells with indirect immunofluorescence 
using IDDM serum as the primary antibody and FITC-labeled anti-human IgG as secondary
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antibody revealed a specific cell surface binding pattern even when the serum was diluted 
from 1:50 to 1:200 (F ig .ll; Fig.12), which demonstrated the binding of immunoglobulin 
IgG in IDDM serum to a surface antigen on neuroblastoma cells.
The morphological changes of the neuronal death caused by EDDM serum, such as 
cytoplasmic condensation, cell shrinkage and lifting (possibly caused by cell membrane 
blebbing) suggested an apoptotic cell death, which could happen as early as 4 hr after 
exposure to IDDM serum. Further study showed that the cell death caused by IDDM serum 
was associated with an increased intracellular free calcium concentration within 10 min in 
some samples. The cytosolic free calcium rise rapidly, as early as 10 sec after exposure to 
IDDM serum and continued to rose for up to 10 min. A DNA fragmentation ladder, which 
can be found in apoptotic cell death, was observed within 4 hr after exposure to cytotoxic 
IDDM serum. The DNA fragmentation ladder was found in cells that had lifted from 
attachment with dishes, but not the cells still attached, suggesting loss o f attachment was 
also an early event in apoptotic cell death in vitro. Those unattached cells could be washed 
and collected by low speed centrifugation, indicating the integrity of the membranes was still 
intact.
Selected classic apoptosis-related proteins, p75, Fas, bcl-2 and p53, were examined 
in this cell line. NGF low affinity receptor p75 was too weakly expressed in NB cells to 
evaluate. However, immunofluorescence with anti-mouse Fas mAb and 
immunoprecipitation with anti-Fas mAb indicated Fas antigen was expressed on the surface 
of N1E-115 NB cells. The cell- surface Fas immunoflurescence binding pattern was totally 
blocked by IDDM serum, indicating that Fas might be one surface antigen recognized by 
IDDM serum. The results from immunoprecipitation with IDDM serum followed by 
Western blot (Fig. 19-B) further supported the possibility that Fas antigen was recognized 
by humoral factors in IDDM serum and was potentially involved in serum toxicity.
*
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 5. Summary & Discussion 77
Discussion
Antibodies against different neuronal tissue components have been reported in many 
neurodegenerative diseases. However, most studies have only demonstrated 
immunoglobulin binding in neuronal tissues, or that there was a higher titer of antibodies 
against neuronal antigens in the circulation of neuropathy patients. It has been unclear 
whether these antibodies truly play a primary role in causing neuronal tissue damage or 
whether they are a secondary response, resulting from the exposure of neuronal antigen by 
damaged tissue. Furthermore, another question is: "what might the mechanism be of 
neuronal tissue damage by these antibodies?" Neuronal cell culture of N1E-115 cells 
provided a model to study both the toxic potential of serum as well as the mechanism of 
neuronal death induced by humoral factors in IDDM serum.
This study demonstrated that humoral factors such as immunoglobulins in EDDM 
patients' sera could inhibit neuronal cell growth and differentiation, indicating humoral 
immune components could directly cause neuronal target tissue damage, even though 
activation of humoral immune components could be a secondary response to unknown 
stimulation. However, none of the studies of immunoglobulin effects, such as protein A 
precipitation to remove immunoglobulins, heat inactivation of complement or testing the 
effect of an immunoglobulin-containing fraction on cell growth, could completely (>75%) 
account for the cytotoxic effect of IDDM serum. Therefore, other possible contributing 
factors, such as low levels of neurotrophic growth factors in the serum of IDDM patients or 
activation of the programmed cell death pathway by another initiator, should also be 
considered.
The different effects of sera on neuronal cell growth and differentiation between 
IDDM and NIDDM patients with neuropathy support the possible role of humoral 
immunopathogenesis in neuropathy of IDDM patients, but not NIDDM. If the humoral 
factors, such as anti-neuronal tissue antibodies, were a secondary manifestation because of 
neuronal tissue destruction and antigen exposure, the test results should be expected to be
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the same in IDDM and NIDDM patients with neuropathy. These inhibitory or toxic effects 
were more prominent in IDDM patients with neuropathy, but inconclusive in IDDM 
patients with no neuropathy. One explanation was that the patients were in different stages 
of neuronal damage with the non-symptomatic patients in a "pre-neuropathic" stage. They 
had not yet had sufficient neuronal loss to cause symptomatic neuropathy. Inhibition was 
not reproduced in NIDDM patients with neuropathy, suggesting a possible heterogeneous 
pathogenesis o f diabetic neuropathy in the two type of diabetes.
These studies indicate that the EDDM serum exerted cytotoxic effects on N1E-115 
neuroblastoma cells by activation of a programmed cell death cascade, apoptosis. From 
temporal analysis in this model, cytosolic free calcium elevation preceded DNA 
fragmentation and cell death. Intracellular calcium elevation had been hypothesized to be an 
early primary event in both programmed cell death and hypoxic-ischemic neuronal injury 
(Kirino, 1994). The consistent finding that IDDM serum caused an increase in cytosol free 
calcium concentration followed by apoptotic cell death, indicated that calcium ion plays a 
critical role in the neurotoxic effect. Increasing evidence indicates that calcium could activate 
latent enzymes that can contribute to the structural changes of apoptosis (Jones et al, 1989; 
Trump et al, 1992). These enzymes include a calcium-dependent nuclear endonuclease that 
can cleave DNA, and a transglutaminase that can crosslink cytosolic proteins. Calcium- 
dependent proteases may also degrade the cytoskeleton. All of the enzymes together appear 
to be responsible for nuclear degradation and cell morphology change. It has been reported 
that IgM autoantibody in IDDM serum can interact with L-type Ca2+ channels to increase 
C a ' influx and cause apoptotic cell death in insulin-secreting cells (Berggren et al., 1993). 
It remains to be determined in our model that the increased cytosolic calcium was induced by 
immunoglobulin (IgG or IgM) and whether the increased cytosolic calcium stimulated by 
IDDM serum resulted from calcium influx through membrane calcium channels or a release 
from intracellular calcium stores. Different calcium channel blockers can be studied to 
determine the type of calcium channel involved and their possible role in apoptotic cell
*
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death.
Homeostasis of multicellular organisms can be controlled not only by the 
proliferation and differentiation of cells but also by cell death. Recent evidence clearly 
indicates that apoptosis may be positively or negatively regulated by certain genes. Many 
growth factors and hormones could regulate cell survival, growth or differentiation. 
Otherwise, cytokines such as Fas ligand or TNF as well as proto-oncogene products and 
transcription factors like c-mys, c-fos, c-jun, p53, bcl-2 may regulate or signal the intrinsic 
cell death program by inducing or inhibiting apoptosis, which functions to remove 
unwanted or non functional cells (Pandey, 1995). Abnormality in the regulation of the cell 
death program may contribute to the pathogenesis of many neurodegenerative diseases, 
autoimmune or neoplastic diseases.
Fas/APO-1, a type I cell surface receptor signaling apoptotic cell death pathway, is 
expressed in many cell lines and mediates apoptosis of susceptible target cells (Weller et al, 
1994). Fas/Fas ligand interaction serves as an important regulatory mechanism in the 
development and function of the immune system. Most studies on Fas show Fas-mediated 
apoptosis in the cytotoxicity of susceptible T-lymphocytes, suggesting that Fas might play a 
critical role in the effector phase of T-dependent immune responses (Hanabuchi et al, 1994). 
Some growth factors and hormones, when bound to their receptors, induce dimerization 
(homodimerization or heterodimerization), which then triggers an intracellular signaling 
cascade with subsequent gene expression. Similarly, the apoptotic cell death-signaling 
pathway from Fas requires the cross-linking of Fas receptors, either with specific antibodies 
to Fas or by Fas ligand trimerization. This is consistent with our observations of Fas 
localization on NB cells treated with cytotoxic IDDM sera.
In our immunocytochemistry study, the cluster of Fas antigen expression on NB 
cells surface in response to IDDM serum stimulation might represent Fas molecular cross- 
linking by the toxic factor in IDDM serum, inducing the cell apoptosis cascade. Treatment 
with anti-Fas mAb caused cell death in a dose-dependent fashion, supporting the hypothesis
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that anti-Fas antibody could induce cell death. Whether Fas expression in NB cells was 
altered by exposure to IDDM serum or there was increased circulating Fas ligand in IDDM 
serum remains to be determined. The observation that Fas receptor is expressed on the 
N1E-115 cell surface and is possibly recognized by IDDM serum suggests that Fas could be 
one of the cell surface antigens recognized by the cytotoxic factor in IDDM serum and 
thereby mediate apoptotic cell death.
Fas antigen expression has not been reported in neurons and has not been 
examined in adrenal medulla, although Fas antigen has been described in some tumor cell 
lines (Yonehara, 1989) and satellite cells of the autonomic ganglia (Owen-Schaub et al., 
1993). Fas was found in brains of patients with Alzheimer-type dementia, mainly 
expressed by a subset of reactive astrocytes. Such astrocytes may undergo the Fas- 
mediated apoptotic process (Nishimura et al., 1995). The existence and the role of Fas in 
neuronal cell death induced by IDDM serum needs to be further confirmed. Fas is a 
member of the NGF receptor/TNF receptor family, which all have a cysteine-rich 
extracellular domain. It is unclear whether the anti-Fas monoclonal antibody will cross 
react with other members in the NGFR/TNFR family on N1E-115 cells because of the 
homology of the extracellular domain and thereby induce cell death, also creating a link 
between the hypothetical apoptotic mechanism and the growth factor deficiency.
We were unable to detect bcl-2 in N IE -115 cells by immunofluorescence. The 
apparent lack o f bcl-2 in the NB-cell line might simply reflect the lack of bcl-2 in 
neuroblastomas, its replacement by another member of the bcl-2 family, eg, bcl-X, or it may 
result from gene loss during tumorigenesis. Furthermore, the lack of bcl-2 may be 
associated with an increased propensity for apoptosis in this cell line. p53 was abundant in 
this cell line as indicated by immunofluorescence, but cytoplasmic distribution raises 
questions about detection of this nuclear protein. However, it is also possible that p53 
could be mutated because the N1E-115 cell line is an adrenergic cell clone derived from a 
neuroblastoma tumor (Amano et al, 1972).
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Our study cannot exclude the possibility that other unknown antigens or death 
factors, such as p75 low affinity NGF receptor, or TNF and its receptors, might also be 
involved. Thus, their role, if any, in the apoptotic neuronal death induced by IDDM 
humoral factors remains to be elucidated. The low-affinity NGF receptor, p75, appears to 
be important for neuronal cell death and survival (Rabizadeh et al., 1993). p75 has some 
sequence similarity to the tumor necrosis factor receptors (TNFR-I and TNFR-II), the 
human cell surface antigen Fas (APO-1), and the B cell antigen CD40, all of which mediate 
cell death through an intracellular "death domain" (Bazzoni, 1996). Lowering of NGF 
concentration, overexpression of p75, or expression of less trkA, the high affinity NGF 
receptor, causes p75 to signal death (Finkel 1996). The type of cell death induced by p75 is 
apoptosis, and neural cell survival is enhanced by binding of NGF to p75 (Rabizadeh et al., 
1993). Recent studies have further supported the concept of p75 as a constitutive regulator 
of apoptosis and suggested that inhibiting p75 expression with antisense oligonucleotides 
can rescue neurons from death (Finkel, 1996). In the N1E-115 cell model, p75 was 
detected weakly, while in preliminary studies trkA expression was strong with 
immunofluorescence assay. More sensitive and quantitative methods will be required to 
examine the possible change of p75 or trkA in response to diabetic sera and their role, if 
any, in induction of apoptosis by IDDM sera.
These studies demonstrated that serum of EDDM patients with neuropathy had a 
greater ability to inhibit neuronal cell growth and differentiation and in some cases induced 
cell death in cultured adrenergic neurons. They indicates that autoimmune-related humoral 
factors inducing apoptotic neuronal death could be one mechanism involved in the 
pathogenesis of diabetic neuropathy. Other investigators have confirmed the appearance of 
autoantibodies before clinical presentation, thus, progressive target cell destruction may 
develop over several years (Boitard, 1992). On this basis, it may be possible to identify 
individuals at high risk for development of IDDM and its complications using specific 
genetic and immunological assays, including the N1E-115 cell model. This raises the
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possibility that effective immunotherapies could be developed to prevent the target cell 
destruction, while the individual still has substantial target cell reserves. As mentioned 
before, autoantibodies against neuronal tissue may not be correlated with islet cytoplasmic 
antibodies (ICA). A method to predict diabetic neuropathy with a more specific neuronal 
cell model may provide a more sensitive, earlier and more accurate diagnosis.
Because the N IE -115 neuroblastoma cell line revealed a neurotoxic effect in 
response to antibodies in IDDM serum, which was correlated with a diagnosis of clinical 
neuropathy and was significantly different from the results in response to NIDDM and 
control serum, this cell culture model might allow early prediction and immunotherapy for 
prevention of diabetic neuropathy. This cell line may also prove to be a useful model to 
further study the mechanism of neuronal death, autoimmune pathogenesis and may allow 
studies of the possible neuronal protective effect of new drugs, neurotrophic factors like 
NGF and to evaluate immune therapy intervention, like intravenous immunoglobulin, for 
treatment of diabetic neuropathy. It is possible in the N IE -115 cell assay that those IDDM 
patients without clinical neuropathy symptoms, but whose sera exhibit neurotoxicity, are in 
a pre-neuropathic state. Thus, this assay may identify those patients at risk for developing 
symptomatic neuropathy. Further longitudinal studies would help to establish the 
significance of these findings. Supporting the possibility that autoimmunity might be 
important in the pathogenesis of diabetic neuropathy was the observation that N1E-115 
cytotoxicity correlates with symptomatic improvement in patients treated with intravenous 
immunoglobulin (IVIg), which has been studied by other investigators in our research 
institutes (unpublished data).
The N1E-115 cell model, like all in vitro cell culture systems, is an advance in 
cellular level biomedical research. It provides a living model to study and observe changes 
of cell morphology, growth, differentiation and related regulating mechanisms in both 
physiological and pathological conditions. The significance of this study lies in 
determining that humoral immune components in sera of IDDM patients can inhibit
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neuronal cell growth and differentiation inhibition and result in cell death, possibly through 
inducing apoptosis. The difference between these studies and most other 
immunopathogenesis studies in neuropathy is that the others showed that antibodies could 
recognize neuronal tissue but could not demonstrate that these antibodies actually damage 
neuronal tissue. In contrast, in the N1E-115 cell model we have shown both neuronal 
toxicity and immunoglobulin causation.
However, the N1E-115 neuroblastoma cell line is a murine tumor cell line. Its 
regulating machinery for cell growth and differentiation might already be altered. Some 
oncogenes could be constitutively turned on while others could be mutated or deleted. 
Another disadvantage is that the sera tested are an unknown mixture. There are 
components which could influence the growth and differentiation of the cells but may not 
be related to diabetes and with varying quantities in the serum among individuals. Thus we 
could not control for all effects of serum in the model. Finally, this model could not reveal 
the possible intrinsic change of diabetic neuronal tissue which may play a role in the 
process of immunopathogenesis of diabetic neuropathy, especially in IDDM patients. Only 
external effectors could be evaluated in these studies.
Conclusion
• Sera from IDDM patients with neuropathy had a higher frequency to inhibit growth and
differentiation of an adrenergic neuronal cell line, N IE -115 neuroblastoma cells, but 
not sera from NIDDM and control subjects. In some cases, the humoral factors in sera 
of IDDM patients with neuropathy induced neuronal death in vitro.
• The neuronal toxicity appeared to be mediated by immunoglobulin in the serum of
IDDM patients and at least partially through a complement-related mechanism.
• The neuronal death caused by IDDM serum seemed to be an apoptotic cell death, which 
is characterized by cell shrinkage, cytoplasmic condensation, cell lifting, increased
•i
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intracellular calcium change and genomic DNA fragmentation.
• Fas, an initiator of apoptosis, could be one cell surface molecule recognized by humoral 
factors in IDDM serum and able to activate the neuronal death pathway.
• Our study supports the hypothesis that immunopathogenesis may be important in the 
development of diabetic neuropathy, thus, indicating that immunotherapy such as IVIg 
treatment could be a practical and effective treatment. Other possible strategies based on 
autoimmune pathogenesis aimed to block the neuronal death pathway should be 
considered and further investigated.
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